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This study shows that flow cytometry analysis of the rate of fluorochrome Rh123 etKlux may be used for detection of cells at initial steps of 
P-glycoprotein expression and of minor subpopulations of multidrug-resistant (MDR) variants in human cell lines. This method also evaluates 
the fraction of low-level MDR cells among peripheral blood leukocytes of patients with chronic myeloid leukemia. The alterations in Pgp function 
were revealed in rat hepatoma cells after short treatment with colchicine. 
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1. INTRODUCTION 
The 170-180 kDa transmembrane glycoprotein (P- 
glycoprotein or Pgp) associated with multidrug resis- 
tance (MDR) is involved in drug transport across the 
plasma membrane of cells [l]. This protein is an energy- 
dependent efflux pump for anticancer drugs, various 
fluorescent dyes and some other substances [2,3]. Pgp 
is expressed in some normal (mainly secretory) tissues, 
in cell lines selected in vitro by drugs, and in drug- 
resistant cancers. It is usually detected by indirect im- 
munofluorescence using anti-Pgp monoclonal antibod- 
ies (Mab) and by mRNA assay [I ,4] However, it is 
necessary not only to reveal the Pgp-positive cells and 
Pgp mRNA, but also to test Pgp-mediated efllux. 
Human malignancies often exhibit low levels of Pgp. 
Therefore it should be possible to detect early stages of 
Pgp activity. A simple test for Pgp-mediated efllux was 
elaborated. It evaluates the efllux of Pgp-transported 
fluorescent dyes from the cells [3]. Here we study 
whether this technique can assess low rates of Pgp- 
mediated efflux in tumor cell lines and in human PBL 
(in CML patients). We also studied Pgp function altera- 
tions in cells treated with the MDR-inducing drug col- 
chicine (CH). 
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2. MATERIALS AND METHODS 
Cells used in the study: human melanoma mS and its drug-resistant 
sub-lines mS-0.02 and mS-0.5 (2-and 130-fold resistant o CH, respec- 
tively); rat hepatoma McA RH 7777 and a 17-fold CH-resistant deriv- 
ative McA RH 7777-0.4. Cell lines and culture conditions were as 
described previously [5]. For Pgp assay the cells were detached from 
the substratum by 0.02 M EDTA. PBL of the patient with CML, blast 
crisis, were prepared as described in [6]. 
Pgp was evaluated by staining the cells with anti-Pgp Mab UIC2 as 
in [7]. To measure Pgp function we have used the fluorescent dye 
Rhodamine 123 (Sigma) (Rh123) and the technique described in [3]. 
For double labeling of the cells by Rh123 and Mab UIC2 the Rhl23- 
stained cells were treated as in [2]. Mab UIC2 (Ig 2a) was the kind gift 
of Dr. E.B. Mechetner (Department of Genetics, Univ. of Illinois, 
Chicago, USA). Conjugates of Ig 2a labeled by Phycoerythrin (PE) 
were the kind gift of Dr. T.M. Thischmann (Johns Hopkins Oncology 
Center, Pediatric Oncology, Baltimore, USA). The cells were analyzed 
in the flow cytometer FACScan (Becton Dickinson). Data were ana- 
lyzed by the Hewlett Packard program. 
3. RESULTS AND DISCUSSION 
We checked whether Rh123 technique can detect cells 
with initial levels of drug resistance and to discriminate 
cells with various drug-resistance levels. The double 
staining of the cells by Rh123 and by UIC2 antibodies 
(Fig. 1) demonstrates Pgp on the 2-fold CH-resistant 
cells and the correlation between the level of Pgp expres- 
sion and the retention of the fluorescent dye. Cells with 
a 2-fold level of drug resistance (Fig. 1 b) differ from the 
wild-type cells as well as from more resistant counter- 
parts (Fig. la,c), This demonstrates that the first steps 
of selection of human melanoma cells for MDR lead to 
isolation of the cells with altered Pgp function. 
In human malignancies only a part of the cells may 
express Pgp. To determine whether comparatively small 
portions of the cells with Pgp hyperfunction may be 
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Fig. 1. Correlation between the retention of Rh123 and expression of 
Pgp in (a) human melanoma mS; (b) 2-fold CH-resistant mS-0.02; (c) 
130-fold CH-resistant mS-0.5. Dot density maps of the cells stained 
with UK2 anti-Pgp Mab indirectly labeled with PE (FL2 
axis = fluorescence intensity of PE) and with Rh123 (FL1 
axis = fluorescence intensity of Rh123). Incubation time in dye-free 
medium was 30 min. 
found in heterogeneous cell populations by Rh123 
staining we studied mixtures of mS and mS-0.5 cells 
(Fig. 2). Flow cytometry shows that the intensity of 
signals both for CH-sensitive and -resistant cells corre- 
lates with the fraction of the cells in cell mixtures (Fig. 
2). 10% of mS-0.5 cells are clearly recognizable. 
We used the cytometric technique to find MDR cells 
in blood and bone marrow of patients with CML. It is 
known that after chemotherapy MDR cells may appear. 
In the blood of patient ‘K’ a part of the cell population 
exhibited Pgp (Fig. 3). The quantity of Pgp-positive cells 
detected by the immunofluorescence method and 
Rh123 staining was approximately the same (Figs. 3 
and 4): nearly half of the cell population was UIC2- 
reactive and excluded Rh123 (Fig. 4a,b). The Pgp func- 
tion in these cells was relatively weak since the dye was 
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Fig. 2. Evaluation of minor CH-resistant cell populations. Logarith- 
mic fluorescence intensity of Rh123 treated (a) mS cells; (b) mS 
(90%) + mS-0.5 (10%); (c) mS (80%) + mS-0.5 (20%). Incubation time 
of the dye-stained cells in dye-free medium was 15 min. 
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Fig. 3. Evaluation of the Pgp expressing cells in the blood of CML patient ‘K’. Dot density maps of the cells stained with (a) mouse IgG2 isotype 
control antibodies; (b) UIC2 Mab indirectly labeled with PE (FL2 axis = fluorescence intensity of PE). 
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Fig. 4. Efllux of Rh123 from the blast cells of CML patient ‘K’ 
(logarithmic fluorescence intensity). Note the part of the histograms 
between the dotted lines. Exposure in dye-free medium for: (a) 15 min; 
(b) 60 min; (c) in Verapamil-supplemented medium (10 pg/ml). 
excluded from the cells slowly (for 60 min; Fig. 4a,b). 
Rh123 et&x was Verapamil-sensitive (Fig. 4c). Thus it 
is possible to determine by the rate of Rh123 ef&_tx both 
the portion of cells with functioning Pgp and the rate 
of Pgp-mediated efIlux. 
It was shown that cytotoxic drugs induce elevation of 
mdrl (Pgp) mRNA in rodent cells [8,9]. We studied 
alterations of Pgp function in response to CH treat- 
ment. Treatment of rat hepatoma McA Rh 7777 cells 
with 0.01 &ml of CH for 24 h increased the fraction 
of Rh123-dull cells in the cell population (Fig. 5a,b). 
Thus CH-treated cells were more effective in dye efflux 
than untreated cells. As Fig. 5c,d show, treatment of 
CH-resistant McA Rh 7777-0.4 by 0.01 yg/ml of CH for 
3 h also resulted in an increase in the proportion of 
dye-excluding cells. It is noteworthy that CH-resistant 
McA Rh 7777-0.4 was selected and propagated continu- 
ously in the medium supplemented with 0.4 &ml of 
CH. Before the experiment CH was omitted from cul- 
ture medium for 48 h. Stimulation of Pgp function by 
a CH concentration 40-fold less than the selective dose 
clearly demonstrates the mechanism of drug resistance 
of these cells. These data also show that using the fluo- 
rescence method it is possible to detect initial alterations 
in Pgp function induced by cytotoxic drugs. 
Our data and the data of other authors [2,3,7] show 
that initial alterations in Pgp function and very early 
stages of MDR can be detected by measurement of 
Rh123 exclusion from the cells. This technique would 
provide adequate information about Pgp-mediated 
mechanisms of cellular drug resistance and the rate of 
Pgp function in the cells, as well as on the proportion 
of MDR cells in heterogeneous cell populations and 
agents influencing Pgp function in the cells. 
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Fig. 5. Influence of CH treatment on Pgp-mediated etllux of Rh123. Logarithmic fluorescence intensity of the cells: (a) of CH untreated rat hepatoma 
McA 7777; (b) rat hepatoma McA 7777 treated with 0.01 @ml CH for 24 h; (c) CH untreated 17-fold CH-resistant rat hepatoma McA 7777-0.4; 
(d) McA 7777-0.4 treated with 0.01 De/ml CH for 3 h. All cells were stained with Rh 123 and then incubated in the dye-free medium for 60 min. . _ 
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